[Risk Factor of Cutaneous Symptoms Associated with Enfortumab Vedotin for Urothelial Carcinoma].

Q4 Medicine
Hiroyuki Honda, Tomohiro Matsuo, Shintaro Mori, Kyohei Araki, Kensuke Mitsunari, Kojiro Ohba, Yasushi Mochizuki, Ryoichi Imamura
{"title":"[Risk Factor of Cutaneous Symptoms Associated with Enfortumab Vedotin for Urothelial Carcinoma].","authors":"Hiroyuki Honda, Tomohiro Matsuo, Shintaro Mori, Kyohei Araki, Kensuke Mitsunari, Kojiro Ohba, Yasushi Mochizuki, Ryoichi Imamura","doi":"10.14989/ActaUrolJap_70_11_361","DOIUrl":null,"url":null,"abstract":"<p><p>In 2021, Enfortumab Vedotin (EV) was approved for the treatment of locally advanced and metastatic urothelial carcinoma (UC) in Japan. Some patients require withdrawal or dose reduction due to cutaneous symptoms associated with EV treatment. Currently, the only reported associations of EV with cutaneous symptoms are pre-treatment performance status (PS) and body weight. However, no report has focused on the association between hematological factors and cutaneous symptoms. We retrospectively examined the occurrence of cutaneous symptoms and associated factors in patients who had been treated with EV for UC at Nagasaki University Hospital between February 2022 and June 2023. We evaluated the six patients with bladder cancer and three cases of upper urinary tract cancer. The median age was 73 [57-85] years. Seven patients had cutaneous reactions with EV treatment, and the median date of onset of the cutaneous symptoms was seven [4 -28] days. PS was better inthe group with skinsymptoms compared with the group without (median : 1.0 vs 3.0), and in those with a higher incidence of eosinophilia or cutaneous symptoms on the previous regimen (71. 4% vs 0%). We suggested that the presence of eosinophilia or cutaneous symptoms at the time of pre-EV regimen administration may be a predictor of the appearance of cutaneous symptoms at the time of EV treatment. The limitation is that it is a single-center, small-case series, which does not allow for a rigorous statistical study.</p>","PeriodicalId":39291,"journal":{"name":"Acta Urologica Japonica","volume":"70 11","pages":"361-366"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Urologica Japonica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14989/ActaUrolJap_70_11_361","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

In 2021, Enfortumab Vedotin (EV) was approved for the treatment of locally advanced and metastatic urothelial carcinoma (UC) in Japan. Some patients require withdrawal or dose reduction due to cutaneous symptoms associated with EV treatment. Currently, the only reported associations of EV with cutaneous symptoms are pre-treatment performance status (PS) and body weight. However, no report has focused on the association between hematological factors and cutaneous symptoms. We retrospectively examined the occurrence of cutaneous symptoms and associated factors in patients who had been treated with EV for UC at Nagasaki University Hospital between February 2022 and June 2023. We evaluated the six patients with bladder cancer and three cases of upper urinary tract cancer. The median age was 73 [57-85] years. Seven patients had cutaneous reactions with EV treatment, and the median date of onset of the cutaneous symptoms was seven [4 -28] days. PS was better inthe group with skinsymptoms compared with the group without (median : 1.0 vs 3.0), and in those with a higher incidence of eosinophilia or cutaneous symptoms on the previous regimen (71. 4% vs 0%). We suggested that the presence of eosinophilia or cutaneous symptoms at the time of pre-EV regimen administration may be a predictor of the appearance of cutaneous symptoms at the time of EV treatment. The limitation is that it is a single-center, small-case series, which does not allow for a rigorous statistical study.

尿路上皮癌与维多汀治疗相关皮肤症状的危险因素
2021年,Enfortumab Vedotin (EV)在日本被批准用于治疗局部晚期和转移性尿路上皮癌(UC)。由于与EV治疗相关的皮肤症状,一些患者需要停药或减量。目前,唯一报道的EV与皮肤症状的关联是治疗前表现状态(PS)和体重。然而,没有报告集中在血液因素和皮肤症状之间的关系。我们回顾性研究了2022年2月至2023年6月期间在长崎大学医院接受EV治疗的UC患者皮肤症状及相关因素的发生情况。我们评估了6例膀胱癌和3例上尿路癌。中位年龄为73岁[57-85]岁。7例患者在EV治疗后出现皮肤反应,皮肤症状出现的中位时间为7[4 -28]天。与无皮肤症状组相比,有皮肤症状组的PS更好(中位数:1.0 vs 3.0),并且在先前方案中嗜酸性粒细胞增多或皮肤症状发生率较高的患者中(71。4% vs 0%)。我们认为,在EV治疗前出现嗜酸性粒细胞增多或皮肤症状可能是EV治疗时皮肤症状出现的预测因子。局限性在于它是一个单中心、小病例系列,不允许进行严格的统计研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Acta Urologica Japonica
Acta Urologica Japonica Medicine-Medicine (all)
CiteScore
0.20
自引率
0.00%
发文量
74
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信